Felipe Mendonça Rocha Barros, Arthur Cardoso Tolentino, Lais Soares Ker Marques, Leandro Xavier de Camargo Schlittler, Karina Diniz Oliveira, Paulo Dalgalarrondo, Lucas Luchesi Barnes, Amilton Dos Santos Junior, Claudio Eduardo Muller Banzato
INTRODUCTION: Clozapine, a second-generation antipsychotic (SGA), is considered the gold standard medication to treat patients with treatment-resistant schizophrenia (TRS). Despite its efficacy, clozapine is associated with adverse effects, notably neutropenia and agranulocytosis. Other hematological adverse effects are less common. Severe anemia is a rare adverse effect seldom reported in the literature and is typically associated with pure red cell aplasia (PRCA). Nevertheless, the benefits of clozapine in managing TRS make rechallenge a reasonable option...
March 19, 2024: Schizophrenia Bulletin